Literature DB >> 31819163

Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery.

Arun Radhakrishnan1, Gowthamarajan Kuppusamy2, Sivasankaran Ponnusankar3, Nikhitha K Shanmukhan4.   

Abstract

Personalized medicine has been a booming area in clinical research for the past decade, in which the detailed information about the patient genotype and clinical conditions were collected and considered to optimize the therapy to prevent adverse reactions. However, the utility of commercially available personalized medicine has not yet been maximized due to the lack of a structured protocol for implementation. In this narrative review, we explain the role of pharmacogenetics in personalized medicine, next-generation personalized medicine, i.e., patient-centric personalized medicine, in which the patient's comfort is considered along with pharmacogenomics to be a primary factor. We extensively discuss the classifications, strategies, tools, and drug delivery systems that can support the implementation of patient-centric personalized medicine from an industrial perspective.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31819163     DOI: 10.1038/s41397-019-0135-8

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  75 in total

1.  Evidence based medicine - new approaches and challenges.

Authors:  Izet Masic; Milan Miokovic; Belma Muhamedagic
Journal:  Acta Inform Med       Date:  2008

Review 2.  From Evidence Based Medicine to Medicine Based Evidence.

Authors:  Ralph I Horwitz; Allison Hayes-Conroy; Roberto Caricchio; Burton H Singer
Journal:  Am J Med       Date:  2017-07-12       Impact factor: 4.965

3.  Adverse drug reaction reporting by doctors in a developing country: a case study from Ghana.

Authors:  G T Sabblah; P Akweongo; D Darko; A N O Dodoo; A M Sulley
Journal:  Ghana Med J       Date:  2014-12

Review 4.  Progress in evidence-based medicine: a quarter century on.

Authors:  Benjamin Djulbegovic; Gordon H Guyatt
Journal:  Lancet       Date:  2017-02-17       Impact factor: 79.321

5.  Are We Ready to Include Organ-Impaired Patients in Oncology Trials? A Clinical Pharmacology Perspective on Recent Recommendations.

Authors:  Joanna C Masters; Peter H Wiernik
Journal:  J Clin Pharmacol       Date:  2018-04-17       Impact factor: 3.126

6.  Personalized medicine: Striding from genes to medicines.

Authors:  Sunita R Nair
Journal:  Perspect Clin Res       Date:  2010-10

7.  Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients.

Authors:  Heather L Forbes; Thomas M Polasek
Journal:  Ther Adv Drug Saf       Date:  2017-07-11

8.  Carrier screening by next-generation sequencing: health benefits and cost effectiveness.

Authors:  Mohammad Azimi; Kyle Schmaus; Valerie Greger; Dana Neitzel; Robert Rochelle; Tuan Dinh
Journal:  Mol Genet Genomic Med       Date:  2016-01-29       Impact factor: 2.183

9.  Modelling science trustworthiness under publish or perish pressure.

Authors:  David Robert Grimes; Chris T Bauch; John P A Ioannidis
Journal:  R Soc Open Sci       Date:  2018-01-10       Impact factor: 2.963

View more
  1 in total

1.  Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction.

Authors:  Camille Couffignal; France Mentré; Julie Bertrand
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.